Efficacy and Safety of Carfilzomib, Pomalidomide, and Dexamethasone

Overview

This retrospective study evaluates the efficacy and safety of the KPd regimen in Chinese patients with relapsed/refractory multiple myeloma (RRMM). The findings indicate a high overall response rate of 82.4% and a median progression-free survival of 13 months, highlighting the regimen's effectiveness despite significant hematologic toxicities.

Background

Multiple myeloma (MM) remains an incurable hematological malignancy, particularly in patients with relapsed/refractory multiple myeloma (RRMM). The combination of carfilzomib and pomalidomide represents a promising treatment option, especially for patients who are refractory to lenalidomide. Understanding the real-world effectiveness of such combinations is crucial for optimizing treatment strategies in heavily pretreated populations.

Data Highlights

Key Findings

• The overall response rate (ORR) for KPd was 82.4% in the study cohort.
• Median progression-free survival (PFS) was reported as 13 months.
• Patients with high-risk cytogenetics and prior daratumumab exposure had significantly influenced treatment responses.
• Hematologic toxicities were the most common adverse events, occurring in 73.5% of patients.
• 58.8% of patients experienced grade 3/4 adverse events.

Clinical Implications

The KPd regimen demonstrates substantial efficacy in heavily pretreated RRMM patients, including those refractory to lenalidomide. However, the high incidence of hematologic toxicities necessitates vigilant monitoring and management strategies to mitigate adverse effects.

Conclusion

Reinforce the balance between efficacy and toxicity in treatment considerations.

Related Resources & Content

1. The ASCO Post, 2014 -- Higher-Dose Carfilzomib Produces ‘Remarkable’ Response Duration in Relapsed/Refractory Multiple Myeloma
2. Blood Cancer Journal, 2021 -- Evaluation of Carfilzomib, Cyclophosphamide, and Dexamethasone as Initial Therapy for High-Risk Transplant-Eligible Multiple Myeloma: Results from a Phase 2 Trial (SGH-MM1)
3. The ASCO Post, 2012 -- Will Carfilzomib Add Value to Multiple Myeloma Treatment?
4. Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1 | Journal of Clinical Oncology
5. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR)
6. The ASCO Post — Treating Earlier to Avoid Progression to Multiple Myeloma
7. Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1 | Journal of Clinical Oncology
8. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - ScienceDirect
9. DailyMed - KYPROLIS- carfilzomib injection, powder, lyophilized, for solution